EN DE
Watch OUE LIPPO HEALTHCARE LTD for free: we tell you when fair value or trend changes.
Data-driven stock valuation

OUE LIPPO HEALTHCARE LTD (5WA) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of OUE LIPPO HEALTHCARE LTD stock S$0.15, price S$0.05, upside +200.0%, quality 52 out of 100. Rating: strongly undervalued. Calculated from audited financials with 13 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare SG · ISIN SG2F86994413

OL OUE LIPPO HEALTHCARE LTD logo Thin data Nov 14, 2026

OUE LIPPO HEALTHCARE LTD

5WA · SG

Cheap (67% below fair value), solid company and rising price: meets all 3 rules.

Get notified free when this changes
Fair value 0.1500 SGD · Strongly undervalued 
Rising price (uptrend) 
Generates free cash flow 
Even on cautious assumptions the value is 90% above the price (0.0950 SGD). 
Quality 52/100 
Mixed Growth (revenue 5y +50.1 %/yr in SGD) 
Moderate debt 
Mixed vs. peers (6/13) 
Changed on Oct 28: S$0.1034 → S$0.1470 
Loss-making · -19.5% net margin (TTM) 
Narrow moat 33/100 · thin data
Thin data 
⚠ Small free float
Watch OUE LIPPO HEALTHCARE LTD for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

0.0500 SGD 0.0190 SGD Fair Value 0.1500 SGD Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.

How to read this chart

60‑month range 0.0190 SGD – 0.0500 SGD · fair‑value band 0.0950 SGD – 0.2750 SGD · the 0.0500 SGD price screens below the 0.1500 SGD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 14, 2026.

Follow OUE LIPPO HEALTHCARE in your weekly email

Every Wednesday you see whether OUE LIPPO HEALTHCARE is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

OUE Healthcare Limited, an investment holding company, owns, operates, and invests in healthcare businesses in Singapore, China, Myanmar, Indonesia, and Japan. It operates through Healthcare Operations, Healthcare Assets, Properties Under Development, and Investments segments.

Show moreShow less

The company is involved in the operation of hospitals and clinics; supply of medical equipment and pharmaceutical products; and rental of investment properties and owned assets.

It also engages in the development of medical facilities, healthcare-related assets, and integrated mixed-used projects; and investment in real estate investment trusts and properties.

The company was formerly known as OUE Lippo Healthcare Limited and changed its name to OUE Healthcare Limited in April 2023. The company was founded in 2010 and is headquartered in Singapore. OUE Healthcare Limited is a subsidiary of OUE Limited.

Stock analysis

OUE LIPPO HEALTHCARE LTD (5WA) currently trades at 0.0500 SGD, while our model-based Fair Value estimate is 0.1500 SGD, implying the stock looks roughly 67% undervalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of 0.2500 SGD per share, and 11 of the 12 models we run sit above the 0.0500 SGD price.

Bear case: the Asset-Based group reads lowest at 0.0300 SGD, and 1 of the 12 models stay below the price. Data coverage for this calculation is low.

Scenario range: 0.0950 SGD (bear) to 0.2750 SGD (bull), the price of 0.0500 SGD sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 52/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

OUE LIPPO HEALTHCARE LTD reported revenue of 152M SGD in FY2025 versus 19.7M SGD in FY2021, a compound +66.8%/yr. Reported net income was −16.9M SGD in FY2025.

Key figures

Market cap 222M SGD (≈ $172M) Micro · P/S ratio 1.43 · EPS (TTM) −0.0100 SGD · Dividend yield 0.8% · Net margin −11.1% · Return on equity −1.6% · Return on assets (EBIT) 5.0% (5-year average) · Operating margin 49.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 33 out of 100 (low confidence).

What moves the price

The share trades at its 52-week high and 108% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −2% fair-value upside, at 200%, 5WA screens cheaper than that median.

Fair Value models

Bear 0.0950 SGD Fair Value 0.1500 SGD Bull 0.2750 SGD
Price 0.0500 SGD · Upside +200.0%
Capped: our models arrive at a very high value here. We deliberately show a more cautious Fair Value.
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF 0.1600 SGD 0.2500 SGD 0.5300 SGD 75
Growth DCF 0.1400 SGD 0.2700 SGD 0.5000 SGD 75
EPV 0.0700 SGD 0.0800 SGD 0.0900 SGD 74
All 13 models by family
DCF Models
FCF DCF 0.1600 SGD 0.2500 SGD 0.5300 SGD 75
5Y Revenue Exit 0.0700 SGD 0.1400 SGD 0.2700 SGD 68
5Y EBITDA Exit 0.1500 SGD 0.3000 SGD 0.5900 SGD 71
10Y Revenue Exit 0.1000 SGD 0.2200 SGD 0.2900 SGD 66
10Y EBITDA Exit 0.1600 SGD 0.3800 SGD 0.7700 SGD 63
Earnings-Based
EPV 0.0700 SGD 0.0800 SGD 0.0900 SGD 74
Multiples
EV/EBIT 0.1200 SGD 0.2000 SGD 0.2800 SGD 64
EV/EBITDA 0.0900 SGD 0.1600 SGD 0.2200 SGD 65
EV/Revenue n/a n/a 0.0300 SGD 50
Asset-Based
NCAV (Graham) 0.0200 SGD 0.0300 SGD 0.0500 SGD 52
Growth DCF
Growth DCF 0.1400 SGD 0.2700 SGD 0.5000 SGD 75
Rev-Margin DCF 0.0800 SGD 0.1600 SGD 0.3400 SGD 67
Economic Profit
ROIC Compounder 0.0800 SGD 0.1200 SGD 0.1500 SGD 72

Open the full fair value analysis →

Quality Score breakdown

Overall quality 52/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 6
How much profit the company makes from its sales and capital
Quality Growth 32
Are margins and returns getting better?
Cashflow 98
Do the profits arrive as real cash?
Financial strength 12
Debt, balance sheet and risk of trouble
Investment 97
Does it invest with discipline instead of growing at any price?
Low Volatility 51
How calm the share price moves, does not count
Price momentum 95
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 100
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 67/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+1.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+50.1%
Start year 2020 (pandemic). Over 10 years: +13.0% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.1%
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+5.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Singapore: IMF forecast 2.0% a year to 2030, 1.7% from 2016 to 2025) that is about +3.5% a year for the price.

Watch 5WA, get fair value alerts →

Compare OUE LIPPO HEALTHCARE LTD with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 249 stocks

Beats the industry median on 6/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 52 · Below median
Fair Value upside +200.0% · Top 25%
Profitability
Return on assets −1.3% · Bottom 25%
Net margin (12 months) −19.5% · Bottom 25%
Operating margin (12 months) 49.7% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 0.2% · Bottom 25%
Dividend yield (12 months) 0.8% · Bottom 25%
Balance sheet
Debt / equity 1.17× · Highest 25%

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/B 0.90× · Cheapest 25%
P/S (12 months) 1.46× · Cheaper than median
Price / free cash flow (fiscal year) 4.4× · Cheapest 25%
EV/EBITDA 5.6× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 33
FUTURE (revenue growth)1 · sector 33
PAST (return on equity)0 · sector 32
HEALTH (low debt)42 · sector 90
DIVIDEND (yield)15 · sector 38

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Fresenius Medical Care AG FMS $22.03 $45.73 +108% vs 5WA
DaVita Inc DVA $174.56 $218.90 +25% vs 5WA
Aier Eye Hospital Group 300015 ¥8.84 ¥10.88 +23% vs 5WA
HCA Healthcare, Inc HCA $499.05 $547.34 +10% vs 5WA
Tenet Healthcare Corporation THC $286.03 $279.20 −2% vs 5WA
The Ensign Group ENSG $188.41 $140.09 −26% vs 5WA
Encompass Health Corporation EHC $140.99 $94.81 −33% vs 5WA
Fresenius SE FRE €53.62 €34.77 −35% vs 5WA
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,526 ₹5,234 −39% vs 5WA
Dr. Sulaiman Al Habib Medical Services Group 4013 212.10 SAR 109.45 SAR −48% vs 5WA

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

OUE LIPPO HEALTHCARE LTD: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "OUE LIPPO HEALTHCARE LTD Fair Value". https://www.fairvalue-calculator.com/stock/5WA

Frequently asked questions

Is OUE LIPPO HEALTHCARE LTD (5WA) overvalued or undervalued?
As of Nov 14, 2026, our model estimates a fair value of 0.1500 SGD versus a price of 0.0500 SGD, about +200% upside (undervalued).
What is the fair value of 5WA?
Our model-based fair value for OUE LIPPO HEALTHCARE LTD is 0.1500 SGD (as of Nov 14, 2026), built from audited fundamentals. The current price: 0.0500 SGD.
What is the quality score of 5WA?
OUE LIPPO HEALTHCARE LTD has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for OUE LIPPO HEALTHCARE LTD (5WA)?
Our model-based price target is the fair value of 0.1500 SGD (as of Nov 14, 2026) from 13 valuation models. Cautious scenario 0.0950 SGD, optimistic scenario 0.2750 SGD. It is a calculation from audited fundamentals, not an analyst target.
What is the OUE LIPPO HEALTHCARE LTD stock forecast for 2026?
Our models put fair value at 0.1500 SGD, about +200% upside versus a price of 0.0500 SGD (undervalued). Cautious scenario 0.0950 SGD, optimistic scenario 0.2750 SGD. The calculation is refreshed regularly with new filings.
What is the revenue of OUE LIPPO HEALTHCARE LTD (5WA)?
OUE LIPPO HEALTHCARE LTD reported trailing-twelve-month revenue of about 153M SGD (latest available figure, as of Nov 14, 2026).
Does OUE LIPPO HEALTHCARE LTD pay a dividend?
OUE LIPPO HEALTHCARE LTD currently shows a dividend yield of 0.76% relative to its recent price (as of Nov 14, 2026).
How much is the dividend of OUE LIPPO HEALTHCARE LTD (5WA)?
OUE LIPPO HEALTHCARE LTD has a dividend yield of 0.8%.
What growth is priced into OUE LIPPO HEALTHCARE LTD (5WA)?
For today's price to be fair in a discounted-cash-flow model, OUE LIPPO HEALTHCARE LTD would have to grow free cash flow by 5.6 % per year for five years (discount rate 11.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew 50.1 % per year. As of Nov 14, 2026.
What discount rate (WACC) does the fair value of 5WA use?
Our models discount OUE LIPPO HEALTHCARE LTD at 11.0 %: a base by market capitalisation (micro), damped by beta 0.45, country premium for Singapore. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For OUE LIPPO HEALTHCARE LTD that is +5.6 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.0 %) and the same formula as our fair value.
How much growth has OUE LIPPO HEALTHCARE LTD (5WA) delivered so far?
Over the past 5 years revenue at OUE LIPPO HEALTHCARE LTD grew 50.1 % a year. The price currently implies free-cash-flow growth of +5.6 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of OUE LIPPO HEALTHCARE LTD (5WA) growing?
The median revenue growth in the sector is +7.3 % a year. That is the yardstick for the growth priced into OUE LIPPO HEALTHCARE LTD (+5.6 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of OUE LIPPO HEALTHCARE LTD (5WA)?
The free-cash-flow yield on the price is 22.98 %: that much free cash flow OUE LIPPO HEALTHCARE LTD produces per unit of market value. When it exceeds the discount rate of our models (11.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of OUE LIPPO HEALTHCARE LTD (5WA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For OUE LIPPO HEALTHCARE LTD it is 0.1500 SGD per share (as of Nov 14, 2026), against a price of 0.0500 SGD. It is the blended result of 13 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit).
Is OUE LIPPO HEALTHCARE LTD stock overvalued or undervalued in 2026?
As of Nov 14, 2026, 5WA trades below its calculated fair value: price 0.0500 SGD, fair value 0.1500 SGD, a gap of about +200% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 5WA?
No. The price is what the market pays today (0.0500 SGD); the fair value is what the company's own numbers justify (0.1500 SGD). For OUE LIPPO HEALTHCARE LTD the two are 0.1000 SGD per share apart. That gap is exactly why we show both numbers side by side.
How much is OUE LIPPO HEALTHCARE LTD worth?
The market values OUE LIPPO HEALTHCARE LTD at about 222M SGD (market capitalisation, as of Nov 14, 2026). Per share that is 0.0500 SGD; our models calculate a fair value of 0.1500 SGD per share.
What do the bullish and bearish scenarios say about 5WA?
Our models span a range for OUE LIPPO HEALTHCARE LTD: cautious scenario 0.0950 SGD, base 0.1500 SGD, optimistic 0.2750 SGD per share (as of Nov 14, 2026, price 0.0500 SGD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of OUE LIPPO HEALTHCARE LTD (5WA)?
Balance-sheet figures for OUE LIPPO HEALTHCARE LTD (as of Nov 14, 2026): return on equity −1.6%, debt of 1.17 per unit of equity. They feed the Quality Score of 52/100, which measures business quality independently of the share price.
How far is 5WA from its 52-week high?
OUE LIPPO HEALTHCARE LTD trades at 0.0500 SGD, at its 52-week high of 0.0500 SGD and 108% above the low of 0.0240 SGD (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of 0.1500 SGD is for.
Which stocks are comparable to OUE LIPPO HEALTHCARE LTD?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is OUE LIPPO HEALTHCARE LTD stock attractive at the current price?
The data as of Nov 14, 2026: price 0.0500 SGD, calculated fair value 0.1500 SGD (+200%), Quality Score 52/100, from 13 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 5WA calculated?
We run OUE LIPPO HEALTHCARE LTD through 13 models from 6 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit. Every model gets the same audited fundamentals; the fair value of 0.1500 SGD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. OUE LIPPO HEALTHCARE LTD currently trades 67% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of OUE LIPPO HEALTHCARE LTD (5WA)?
The closing price on Nov 16, 2026 was 0.0500 SGD. Our model-based fair value is 0.1500 SGD, about +200% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with OUE LIPPO HEALTHCARE LTD right now?
The price is below even our cautious bear case (0.0950 SGD). The market is more pessimistic than our downside scenario. The model range is unusually wide (0.0950 SGD to 0.2750 SGD). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (52/100) at a price below fair value, the discount is the argument here, not the business quality.

Key figures of OUE LIPPO HEALTHCARE LTD

How large is the market capitalisation of OUE LIPPO HEALTHCARE LTD (5WA)?
The market capitalisation of OUE LIPPO HEALTHCARE LTD is 222M SGD (≈ $172M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of OUE LIPPO HEALTHCARE LTD (5WA)?
The price-to-sales ratio of OUE LIPPO HEALTHCARE LTD is 1.43 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of OUE LIPPO HEALTHCARE LTD (5WA)?
Earnings per share at OUE LIPPO HEALTHCARE LTD are −0.0100 SGD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of OUE LIPPO HEALTHCARE LTD (5WA)?
The dividend yield of OUE LIPPO HEALTHCARE LTD is 0.8%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of OUE LIPPO HEALTHCARE LTD (5WA)?
The net margin of OUE LIPPO HEALTHCARE LTD is −11.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of OUE LIPPO HEALTHCARE LTD (5WA)?
The return on equity (ROE) of OUE LIPPO HEALTHCARE LTD is −1.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of OUE LIPPO HEALTHCARE LTD (5WA)?
On an EBIT basis the return on assets of OUE LIPPO HEALTHCARE LTD is 5.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of OUE LIPPO HEALTHCARE LTD (5WA)?
The operating margin of OUE LIPPO HEALTHCARE LTD is 49.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at OUE LIPPO HEALTHCARE LTD (5WA)?
Revenue at OUE LIPPO HEALTHCARE LTD is growing 0.2% versus a year earlier (3y avg +8.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at OUE LIPPO HEALTHCARE LTD (5WA)?
Earnings per share at OUE LIPPO HEALTHCARE LTD are down 75.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does OUE LIPPO HEALTHCARE LTD (5WA) carry?
The net debt of OUE LIPPO HEALTHCARE LTD is 465M SGD (fiscal year 2025, ≈ 9.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch OUE LIPPO HEALTHCARE LTD in the live analysis

One click puts OUE LIPPO HEALTHCARE LTD on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.